NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $70,995 | +285.7% | 119,200 | +272.5% | 0.00% | – |
| Q2 2023 | $18,405 | +5.2% | 32,000 | +28.5% | 0.00% | – |
| Q1 2023 | $17,501 | -93.8% | 24,900 | -80.0% | 0.00% | -100.0% |
| Q4 2022 | $281,829 | -58.6% | 124,703 | -41.3% | 0.00% | -66.7% |
| Q3 2022 | $680,000 | +129.0% | 212,417 | +171.6% | 0.01% | +100.0% |
| Q2 2022 | $297,000 | -46.2% | 78,200 | +91.6% | 0.00% | -40.0% |
| Q4 2021 | $552,000 | -85.0% | 40,810 | -80.1% | 0.01% | -87.2% |
| Q3 2021 | $3,687,000 | +265.0% | 205,309 | +249.0% | 0.04% | +254.5% |
| Q2 2021 | $1,010,000 | +4.8% | 58,829 | +22.1% | 0.01% | -8.3% |
| Q1 2021 | $964,000 | -60.7% | 48,199 | -54.5% | 0.01% | -63.6% |
| Q2 2020 | $2,456,000 | +170.8% | 106,014 | +112.9% | 0.03% | +22.2% |
| Q3 2019 | $907,000 | -59.0% | 49,800 | +139.4% | 0.03% | -83.7% |
| Q1 2018 | $2,211,000 | +489.6% | 20,804 | -4.6% | 0.17% | +159.4% |
| Q3 2016 | $375,000 | – | 21,803 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |